Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

CRNX

Crinetics Pharmaceuticals Inc

May 10 • 04:00PM ET

48.00

Dollar change -1.42
Percentage change -2.87	%

Healthcare • Biotechnology • USA • NASD

Stock Detail • Compare Perf. • Revenue • Options Chain • Save to Portfolio • Create Alert

Held by: VTI IWM VXF IWN IBB SCHA VTWO VHT LABU IWC

Scroll to Statements

Index	RUT	P/E	-	EPS (ttm)	-3.77	Insider Own	7.45%	Shs Outstand	78.74M	Perf Week	1.69%
Market Cap	3.78B	Forward P/E	-	EPS next Y	-3.79	Insider Trans	-5.53%	Shs Float	72.87M	Perf Month	-0.06%
Income	-235.46M	PEG	-	EPS next Q	-0.86	Inst Own	89.52%	Short Float	6.73%	Perf Quarter	21.64%
Sales	0.00M	P/S	-	EPS this Y	3.69%	Inst Trans	1.41%	Short Ratio	5.91	Perf Half Y	68.72%
Book/sh	11.14	P/B	4.31	EPS next Y	-6.57%	ROA	-36.44%	Short Interest	4.91M	Perf Year	105.66%
Cash/sh	11.44	P/C	4.19	EPS next 5Y	-	ROE	-40.76%	52W Range	15.76 - 51.29	Perf YTD	34.91%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-10.59%	ROI	-25.55%	52W High	-6.41%	Beta	0.67
Dividend TTM	-	Quick Ratio	17.72	Sales past 5Y	64.83%	Gross Margin	-105.50%	52W Low	204.57%	ATR (14)	2.24
Dividend Ex-Date	-	Current Ratio	17.72	EPS Y/Y TTM	-15.15%	Oper. Margin	-38983.28%	RSI (14)	57.74	Volatility	4.53% 4.67%
Employees	290	Debt/Eq	0.06	Sales Y/Y TTM	-100.00%	Profit Margin	-	Recom	1.21	Target Price	61.64
Option/Short	Yes / Yes	LT Debt/Eq	0.05	EPS Q/Q	-8.52%	Payout	-	Rel Volume	1.19	Prev Close	49.42
Sales Surprise	220.00%	EPS Surprise	-14.87%	Sales Q/Q	-	Earnings	May 09 AMC	Avg Volume	829.51K	Price	48.00
SMA20	6.85%	SMA50	8.24%	SMA200	44.84%	Trades		Volume	988,384	Change	-2.87%

Date	Action	Analyst	Rating Change	Price Target Change
Mar-06-24	Initiated	Citigroup	Buy	$68
Jan-16-24	Initiated	Morgan Stanley	Overweight	$50
Dec-21-23	Initiated	Jefferies	Hold	$35
Nov-20-23	Resumed	JP Morgan	Overweight	$35
Oct-24-23	Resumed	Cantor Fitzgerald	Overweight	$52 → $50
Aug-31-23	Initiated	Oppenheimer	Outperform	$40
Apr-24-23	Initiated	Piper Sandler	Overweight	$56
Mar-30-23	Initiated	Robert W. Baird	Outperform	$48
Nov-30-21	Initiated	JMP Securities	Mkt Outperform	$43
Nov-23-21	Initiated	Evercore ISI	Outperform	$68
Jun-18-21	Upgrade	JP Morgan	Neutral → Overweight	$28
Dec-23-19	Initiated	ROTH Capital	Buy	$37
Feb-14-19	Initiated	H.C. Wainwright	Buy	$35
Aug-13-18	Initiated	Piper Jaffray	Overweight	$40
Aug-13-18	Initiated	Leerink Partners	Outperform	$43
Aug-13-18	Initiated	JP Morgan	Neutral	$29

Show Previous Ratings

May-10-24 05:38PM	Crinetics Pharmaceuticals Announces May 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
05:03PM	Crinetics Pharmaceuticals Insider Sold Shares Worth $5,307,931, According to a Recent SEC Filing (MT Newswires)
12:47PM	Crinetics Pharmaceuticals Inc (CRNX) Reports Q1 2024 Financial Results (GuruFocus.com)
May-09-24 08:55PM	CRNX Stock Earnings: Crinetics Pharmaceuticals Misses EPS, Beats Revenue for Q1 2024 (InvestorPlace)
05:35PM	Crinetics Pharmaceuticals, Inc. (CRNX) Reports Q1 Loss, Misses Revenue Estimates (Zacks)
05:03PM	Loading…
05:03PM	Crinetics Pharmaceuticals Q1 Net Loss Widens (MT Newswires)
04:05PM	Crinetics Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Business Update (GlobeNewswire)
May-08-24 04:05PM	Crinetics Pharmaceuticals to Present Advancements from Atumelnant (CRN04894) and Paltusotine Development Programs at ENDO 2024 (GlobeNewswire) +6.78%
May-07-24 08:55AM	Piper Sandler Adjusts Price Target on Crinetics Pharmaceuticals to $97 From $56, Maintains Overweight Rating (MT Newswires)
May-02-24 04:05PM	Crinetics Pharmaceuticals to Report First Quarter 2024 Financial Results on May 9, 2024 (GlobeNewswire)
Apr-11-24 04:05PM	Crinetics Pharmaceuticals Announces April 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Mar-28-24 08:10AM	Insiders Are Dumping These 5 Healthcare Stocks (Insider Monkey) +5.36%
Mar-26-24 07:01PM	Insider Sell: COO Jeff Knight Sells 32,359 Shares of Crinetics Pharmaceuticals Inc (CRNX) (GuruFocus.com)
Mar-22-24 07:02PM	Insider Sell: Chief Medical and Development Officer Dana Pizzuti Sells 15,089 Shares of ... (GuruFocus.com)
07:02PM	Director Matthew Fust Sells 60,000 Shares of Crinetics Pharmaceuticals Inc (CRNX) (GuruFocus.com)
02:32AM	Loading…
Mar-21-24 02:32AM	Crinetics Pharmaceuticals Inc CFO Marc Wilson Sells 6,942 Shares (GuruFocus.com)
Mar-20-24 11:46AM	Crinetics (CRNX) Up as Second Acromegaly Study Meets Goals (Zacks)
05:14AM	Crinetics Pharmaceuticals (CRNX) Stock Jumps 19.1%: Will It Continue to Soar? (Zacks)
Mar-19-24 04:48PM	Endocrine Disease-Focused Crinetics Pharmaceuticals Stock Soars On Tuesday - Here's Why (Benzinga) +19.11%
04:03PM	Crinetics Stock Jets 19% Higher, Reversing A Three-Week Decline On Its Phase 3 Win (Investor's Business Daily)
08:08AM	Biotech Stock Crinetics Jets Higher On Second Phase 3 Trial Win (Investor's Business Daily)
06:16AM	UPDATE 2-Crinetics' hormonal disorder drug succeeds in late-stage study (Reuters)
06:08AM	Crinetics Pharma's hormonal disorder drug meets main goal in late-stage study (Reuters)
06:00AM	Crinetics' Once-Daily Oral Paltusotine Achieved the Primary and All Secondary Endpoints in the Phase 3 PATHFNDR-2 Study in Acromegaly Patients (GlobeNewswire)
Mar-12-24 04:05PM	Crinetics Announces Positive Topline Results from Phase 2 Trial of Paltusotine for the Treatment of Carcinoid Syndrome (GlobeNewswire)
Mar-11-24 04:05PM	Crinetics Pharmaceuticals Announces March 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Mar-01-24 08:57AM	Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) Q4 2023 Earnings Call Transcript (Insider Monkey) +12.43%
Feb-28-24 04:36PM	Crinetics Pharmaceuticals Inc (CRNX) Reports Increased R&D Investment Amidst Net Loss ... (GuruFocus.com) +5.66%
04:05PM	Crinetics Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update (GlobeNewswire)
08:00AM	Crinetics Pharmaceuticals Announces Oversubscribed $350 Million Private Placement (GlobeNewswire)
03:14AM	Loading…
Feb-15-24 03:14AM	Steven Cohen Adjusts Position in Crinetics Pharmaceuticals Inc (GuruFocus.com)
Feb-14-24 04:05PM	Crinetics Pharmaceuticals to Report Fourth Quarter and Full Year 2023 Financial Results on February 28, 2024 (GlobeNewswire)
Feb-12-24 04:05PM	Crinetics Pharmaceuticals Announces February 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Jan-26-24 11:01PM	Crinetics Pharmaceuticals Inc's Chief Scientific Officer Sells Company Shares (GuruFocus.com)
Jan-13-24 05:03AM	Crinetics Pharmaceuticals Inc Insider Sells Shares (GuruFocus.com)
Jan-10-24 04:33PM	Crinetics Pharmaceuticals Announces January 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Jan-05-24 03:03AM	Insider Sell: Chief Med and Dev Officer Dana Pizzuti Sells 14,375 Shares of Crinetics ... (GuruFocus.com)
Jan-03-24 08:00AM	Crinetics Pharmaceuticals to Participate in the 42nd Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Dec-29-23 07:02AM	Crinetics Pharmaceuticals Inc's Chief Scientific Officer Sells Shares (GuruFocus.com)
Dec-23-23 05:01AM	Insider Sell: Chief Med and Dev Officer Dana Pizzuti Sells 9,583 Shares of Crinetics ... (GuruFocus.com)
Dec-18-23 04:05PM	Crinetics Announces Positive Initial Findings from Ongoing Open-Label Phase 2 Study of Paltusotine for the Treatment of Carcinoid Syndrome (GlobeNewswire)
Dec-11-23 04:05PM	Crinetics Pharmaceuticals Announces December 2023 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Dec-03-23 05:25AM	12 Stocks Billionaire Steve Cohen Just Bought and Sold (Insider Monkey)
Nov-20-23 04:05PM	Crinetics Pharmaceuticals to Participate in Upcoming Investor Conferences (GlobeNewswire)
Nov-17-23 08:39AM	Billionaire Steve Cohen Goes Big on These 2 Strong Buy Stocks Heres Why You Should Follow (TipRanks) +5.82%
Nov-10-23 05:00PM	Crinetics Pharmaceuticals Announces November 2023 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Nov-09-23 05:45AM	Crinetics Pharmaceuticals Inc (CRNX) Reports Q3 2023 Results: Phase 3 Success and Financial Growth (GuruFocus.com) -6.19%
Nov-08-23 09:55AM	Wall Street Analysts See a 56.94% Upside in Crinetics Pharmaceuticals, Inc. (CRNX): Can the Stock Really Move This High? (Zacks)
08:50AM	Here's What Could Help Crinetics Pharmaceuticals, Inc. (CRNX) Maintain Its Recent Price Strength (Zacks)
Nov-07-23 04:05PM	Crinetics Pharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Corporate Update (GlobeNewswire)
Nov-04-23 05:03AM	Insider Sell: CFO Marc Wilson Sells 10,000 Shares of Crinetics Pharmaceuticals Inc (CRNX) (GuruFocus.com)
Oct-23-23 09:55AM	Wall Street Analysts Think Crinetics Pharmaceuticals, Inc. (CRNX) Could Surge 55.53%: Read This Before Placing a Bet (Zacks)
08:50AM	What Makes Crinetics Pharmaceuticals, Inc. (CRNX) a Good Fit for 'Trend Investing' (Zacks)
Oct-20-23 01:02AM	Insider Sell: Chief Medical Officer Alan Krasner Sells 7,000 Shares of Crinetics Pharmaceuticals Inc (GuruFocus.com) +5.92%
Oct-11-23 09:00AM	Young Adults and Pancreatic Cancer: What the 80% Rise in Diagnoses Means for Future Treatment (PR Newswire)
Oct-10-23 05:00PM	Crinetics Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Oct-03-23 07:00AM	7 Speculative Stocks Set to Explode Higher (InvestorPlace)
Sep-28-23 11:18AM	Crinetics (CRNX) Stock Surges 70% in a Month: Here's Why (Zacks)
Sep-20-23 08:00AM	Crinetics Pharmaceuticals to Participate in the Cantor Global Healthcare Conference 2023 (GlobeNewswire)
Sep-15-23 08:37AM	Why Crinetics Pharmaceuticals Stock Soared This Week (Motley Fool)
Sep-12-23 10:26PM	Crinetics Pharmaceuticals Announces Pricing of Upsized Public Offering of Common Stock (GlobeNewswire) +17.29%
Sep-11-23 04:04PM	Crinetics Pharmaceuticals Just Scored A Much-Needed Win And Soared 63% (Investor's Business Daily) +63.31%
04:01PM	Crinetics Pharmaceuticals Announces Proposed Public Offering of Common Stock (GlobeNewswire)
12:57PM	Why Shares of Crinetics Pharmaceuticals Are Jumping Monday (Motley Fool)
06:00AM	Crinetics Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
05:43AM	Crinetics shares surge after "positive" hormonal disorder drug trial results (Investing.com)
Sep-10-23 10:00AM	Crinetics Once-Daily Oral Paltusotine Achieved the Primary and All Secondary Endpoints in the Phase 3 PATHFNDR-1 Study Evaluating Treatment of Patients with Acromegaly (GlobeNewswire)
Sep-05-23 08:55PM	Oppenheimer Says These 2 Stocks Could Double Your Money Heres Why They Could Jump (TipRanks)
Aug-13-23 09:02AM	Will Crinetics Pharmaceuticals (NASDAQ:CRNX) Spend Its Cash Wisely? (Simply Wall St.)
Aug-10-23 05:34PM	Crinetics Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Aug-08-23 07:00AM	Crinetics Pharmaceuticals Reports Second Quarter 2023 Financial Results and Provides Corporate Update (GlobeNewswire)
Jul-31-23 08:01AM	Crinetics Hosting Key Opinion Leader Webinar to Discuss the Current Treatment Landscape and Unmet Need in Acromegaly (GlobeNewswire)
Jul-10-23 04:18PM	Crinetics Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +5.73%
Jun-21-23 07:59AM	New Data Demonstrating Stable Biochemical and Symptom Levels with Two-Years of Oral Paltusotine Administration Presented at ENDO 2023 (GlobeNewswire)
Jun-12-23 07:30AM	Crinetics Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Jun-09-23 07:30AM	Crinetics to Highlight Broad Pipeline at ENDO 2023 (GlobeNewswire)
May-10-23 04:21PM	Crinetics Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
May-06-23 08:07AM	Crinetics Pharmaceuticals First Quarter 2023 Earnings: Revenues Beat Expectations, EPS Lags (Simply Wall St.)
May-04-23 07:35PM	Crinetics Pharmaceuticals, Inc. (CRNX) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
04:05PM	Crinetics Pharmaceuticals Reports First Quarter 2023 Financial Results and Provides Corporate Update (GlobeNewswire)
10:00AM	Earnings Preview: Crinetics Pharmaceuticals, Inc. (CRNX) Q1 Earnings Expected to Decline (Zacks)
Apr-16-23 09:34AM	The past year for Crinetics Pharmaceuticals (NASDAQ:CRNX) investors has not been profitable (Simply Wall St.)
Apr-10-23 04:31PM	Crinetics Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Mar-28-23 03:57PM	Top 10 Growth Stocks in Biotech (Insider Monkey)
Mar-10-23 04:37PM	Crinetics Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) -5.05%
Mar-06-23 07:05AM	We Think Crinetics Pharmaceuticals (NASDAQ:CRNX) Can Afford To Drive Business Growth (Simply Wall St.)
Feb-28-23 05:25PM	Crinetics Pharmaceuticals, Inc. (CRNX) Reports Q4 Loss, Lags Revenue Estimates (Zacks)
04:05PM	Crinetics Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update (GlobeNewswire)
Feb-10-23 05:21PM	Crinetics Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
08:01AM	Crinetics Pharmaceuticals to Participate in the SVB Securities Global Biopharma Conference (GlobeNewswire)
Jan-10-23 04:48PM	Crinetics Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Jan-09-23 08:01AM	Crinetics Pharmaceuticals to Present Corporate and Clinical Update at 41st Annual J.P. Morgan Healthcare Conference (GlobeNewswire) -5.59%
Dec-12-22 04:01PM	Crinetics Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Nov-28-22 08:00AM	Crinetics Pharmaceuticals Provides Update on CRN04777 Program (GlobeNewswire) -5.86%
Nov-22-22 08:00AM	Crinetics Pharmaceuticals to Participate in the 5th Annual Evercore ISI HealthCONx Conference (GlobeNewswire)
Nov-14-22 09:15AM	Crinetics Pharmaceuticals, Inc. (CRNX) Reports Q3 Loss, Misses Revenue Estimates (Zacks)
08:00AM	Crinetics Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Corporate Update (GlobeNewswire)
Nov-10-22 04:30PM	Crinetics Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +10.52%
Nov-06-22 07:26AM	Shareholders in Crinetics Pharmaceuticals (NASDAQ:CRNX) are in the red if they invested a year ago (Simply Wall St.)
Oct-13-22 08:00AM	Enrollment Completed in Phase 3 PATHFNDR-1 Study Evaluating Oral Paltusotine for the Treatment of Acromegaly (GlobeNewswire)

Crinetics Pharmaceuticals, Inc. operates as a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. Its product candidate, CRN00808, is an oral nonpeptide somatostatin agonist for the treatment of acromegaly. The firm is also developing other oral nonpeptide somatostatin agonists for neuroendocrine tumors and hyperinsulinism, as well as an oral nonpeptide ACTH antagonist for the treatment of Cushing's disease. The company was founded by R. Scott Struthers, Yun-Fei Zhu and Stephen F. Betz in 2008 and is headquartered in San Diego, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Struthers Richard Scott	President & CEO	May 08 '24	Option Exercise	9.28	107,448	997,117	364,933	May 10 04:57 PM
Struthers Richard Scott	President & CEO	May 08 '24	Sale	49.40	107,448	5,307,931	257,485	May 10 04:57 PM
Pizzuti Dana	Chief Med and Dev Officer	Apr 15 '24	Option Exercise	16.89	14,375	242,794	42,161	Apr 17 04:36 PM
Struthers Richard Scott	President & CEO	Apr 15 '24	Option Exercise	1.91	20,000	38,200	257,835	Apr 17 04:30 PM
Pizzuti Dana	Chief Med and Dev Officer	Apr 15 '24	Sale	44.47	14,375	639,256	27,786	Apr 17 04:36 PM
Struthers Richard Scott	President & CEO	Apr 04 '24	Option Exercise	9.28	40,951	380,025	278,786	Apr 08 05:09 PM
Struthers Richard Scott	President & CEO	Apr 04 '24	Sale	49.17	40,951	2,013,561	237,835	Apr 08 05:09 PM
Okey Stephanie	Director	Mar 28 '24	Option Exercise	18.29	17,500	320,075	23,500	Apr 02 04:35 PM
Okey Stephanie	Director	Mar 28 '24	Sale	46.38	17,500	811,650	6,000	Apr 02 04:35 PM
Knight Jeff E.	Chief Operating Officer	Mar 22 '24	Option Exercise	23.98	30,000	719,400	84,939	Mar 26 04:30 PM
Knight Jeff E.	Chief Operating Officer	Mar 22 '24	Sale	44.31	32,359	1,433,675	52,580	Mar 26 04:30 PM
Fust Matthew K	Director	Mar 20 '24	Option Exercise	20.92	60,000	1,254,975	36,036	Mar 22 04:31 PM
Pizzuti Dana	Chief Med and Dev Officer	Mar 20 '24	Option Exercise	16.89	14,375	242,794	38,500	Mar 22 04:52 PM
Fust Matthew K	Director	Mar 20 '24	Sale	44.14	60,000	2,648,150	18,536	Mar 22 04:31 PM
Pizzuti Dana	Chief Med and Dev Officer	Mar 20 '24	Sale	44.06	15,089	664,763	27,786	Mar 22 04:52 PM
Wilson Marc	CFO	Mar 19 '24	Sale	42.91	6,942	297,881	110,630	Mar 20 06:32 PM
Betz Stephen F.	Chief Scientific Officer	Jan 25 '24	Sale	37.26	3,000	111,780	73,298	Jan 26 05:50 PM
Betz Stephen F.	Chief Scientific Officer	Jan 10 '24	Sale	37.65	3,000	112,950	76,298	Jan 12 04:12 PM
Pizzuti Dana	Chief Med and Dev Officer	Jan 03 '24	Option Exercise	16.89	14,375	242,794	20,286	Jan 04 04:45 PM
Pizzuti Dana	Chief Med and Dev Officer	Jan 03 '24	Sale	35.00	14,375	503,125	5,911	Jan 04 04:45 PM
Wilson Marc	CFO	Jan 02 '24	Option Exercise	9.28	10,000	92,800	106,055	Jan 04 04:43 PM
Wilson Marc	CFO	Jan 02 '24	Sale	35.47	10,000	354,700	96,055	Jan 04 04:43 PM
Betz Stephen F.	Chief Scientific Officer	Dec 26 '23	Sale	35.89	3,000	107,670	79,298	Dec 27 05:20 PM
Pizzuti Dana	Chief Med and Dev Officer	Dec 21 '23	Option Exercise	16.89	9,583	161,857	15,494	Dec 22 06:45 PM
Pizzuti Dana	Chief Med and Dev Officer	Dec 21 '23	Sale	34.57	9,583	331,284	5,911	Dec 22 06:45 PM
Betz Stephen F.	Chief Scientific Officer	Dec 11 '23	Sale	32.87	3,000	98,610	82,298	Dec 13 04:44 PM
Betz Stephen F.	Chief Scientific Officer	Nov 27 '23	Sale	31.84	3,000	95,520	85,298	Nov 29 04:31 PM
Struthers Richard Scott	President & CEO	Nov 09 '23	Option Exercise	1.91	50,000	95,500	185,522	Nov 13 04:33 PM
Struthers Richard Scott	President & CEO	Nov 03 '23	Option Exercise	9.28	199,082	1,847,481	334,604	Nov 06 06:02 PM
Struthers Richard Scott	President & CEO	Nov 03 '23	Sale	30.56	199,082	6,083,946	135,522	Nov 06 06:02 PM
Struthers Richard Scott	President & CEO	Nov 02 '23	Option Exercise	9.28	918	8,519	136,440	Nov 06 06:02 PM
Struthers Richard Scott	President & CEO	Nov 02 '23	Sale	29.95	918	27,494	135,522	Nov 06 06:02 PM
Wilson Marc	CFO	Nov 01 '23	Option Exercise	9.28	10,000	92,800	105,601	Nov 03 07:38 PM
Wilson Marc	CFO	Nov 01 '23	Sale	28.75	10,000	287,500	95,601	Nov 03 07:38 PM
Krasner Alan Seth	Chief Medical Officer	Oct 17 '23	Option Exercise	12.01	7,000	84,070	50,210	Oct 19 05:01 PM
Krasner Alan Seth	Chief Medical Officer	Oct 17 '23	Sale	30.00	7,000	210,000	43,210	Oct 19 05:01 PM
Struthers Richard Scott	President & CEO	Aug 14 '23	Option Exercise	1.91	10,000	19,100	135,522	Aug 16 04:30 PM
Struthers Richard Scott	President & CEO	Jul 13 '23	Sale	20.35	14,157	288,095	630,805	Jul 13 04:56 PM
Struthers Richard Scott	President & CEO	Jul 12 '23	Sale	20.17	11,459	231,128	644,962	Jul 13 04:56 PM
Struthers Richard Scott	President & CEO	Jul 11 '23	Sale	20.14	24,384	491,094	656,421	Jul 13 04:56 PM
Wilson Marc	CFO	Jun 20 '23	Option Exercise	9.28	20,000	185,600	115,158	Jun 21 05:32 PM
Wilson Marc	CFO	Jun 20 '23	Sale	19.97	30,922	617,403	95,158	Jun 21 05:32 PM
Struthers Richard Scott	President & CEO	Jun 16 '23	Sale	20.81	50,000	1,040,500	680,805	Jun 21 05:27 PM
Vivaldi Coelho Rogerio	Director	Jun 08 '23	Buy	22.06	5,000	110,300	5,000	Jun 09 08:00 AM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

CRNX

Crinetics Pharmaceuticals Inc

Upgrade your FINVIZ experience